Anti-CD20 antibody plus chemo aids CLL with comorbidity Oncology Nurse Advisor (HealthDay News) -- For patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions, combining an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy is associated with improved outcomes, according to ... |
